Intercept Pharmaceuticals Inc (ICPT) Stake Increased by Legal & General Group Plc

Legal & General Group Plc lifted its stake in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 48.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,856 shares of the biopharmaceutical company’s stock after buying an additional 2,882 shares during the quarter. Legal & General Group Plc’s holdings in Intercept Pharmaceuticals were worth $514,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Intercept Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its position in shares of Intercept Pharmaceuticals by 85.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 3,136 shares during the last quarter. Asymmetry Capital Management L.P. purchased a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter worth approximately $3,580,000. FNY Managed Accounts LLC purchased a new stake in shares of Intercept Pharmaceuticals during the 3rd quarter worth approximately $417,000. Finally, Fox Run Management L.L.C. lifted its position in shares of Intercept Pharmaceuticals by 48.3% during the 3rd quarter. Fox Run Management L.L.C. now owns 8,900 shares of the biopharmaceutical company’s stock worth $517,000 after buying an additional 2,900 shares during the last quarter. Institutional investors and hedge funds own 73.76% of the company’s stock.

Shares of Intercept Pharmaceuticals Inc (ICPT) opened at $58.21 on Friday. Intercept Pharmaceuticals Inc has a 12-month low of $54.98 and a 12-month high of $135.59. The company has a market cap of $1,460.00, a price-to-earnings ratio of -3.93 and a beta of -2.05. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The firm had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. During the same quarter in the prior year, the firm earned ($3.59) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 697.9% on a year-over-year basis. equities analysts forecast that Intercept Pharmaceuticals Inc will post -13.36 earnings per share for the current year.

ICPT has been the subject of several recent analyst reports. Wells Fargo & Co restated an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Cantor Fitzgerald restated an “underweight” rating and set a $69.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Jefferies Group restated a “buy” rating and set a $275.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Robert W. Baird restated an “outperform” rating and set a $332.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Finally, BMO Capital Markets restated an “outperform” rating and set a $221.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $141.58.

ILLEGAL ACTIVITY WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3128153/intercept-pharmaceuticals-inc-icpt-stake-increased-by-legal-general-group-plc.html.

Intercept Pharmaceuticals Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.